Hepatitis C prevalence studied by polymerase chain reaction and serological methods in haemodialysis patients in Mazandaran, Iran

Singapore Medical Journal

Volumn 49, Issue 11, 2008, Pages 921-923

  Makhlough, Atieh ^a   Jamshidi, M ^a   Mahdavi, M R ^b  

^a MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Enzyme linked immunosorbent assay; Haemodialysis; Hepatitis C virus; Polymerase chain reaction; Serological methods

Indexed keywords

HEPATITIS C ANTIBODY;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMODIALYSIS; HEPATITIS C; HUMAN; IRAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREVALENCE; SEROLOGY; TREATMENT DURATION;

ADULT; AGED; CLINICAL CHEMISTRY TESTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; IRAN; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PREVALENCE; RENAL DIALYSIS;

EID: 57149111698     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Olmer M, Bouchouareb D, Zandotti C, De Micco P, Lamballerie X. Transmission of the hepatitis C virus in a hemodialysis unit: evidence for nosocomial infection. Clin Nephrol 1996; 47:263-70.
2. Natov SN, Pereira BJ. Hepatitis C in dialysis patients. Adv Ren Replace Ther 1996; 3:275-83.
3. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. J Hepatol 2002; 36:3-10.
4. Masuko K, Okuda K, Meguro T, et al. Hepatitis C virus antibodies, viral RNA and genotypes in sera from patients on maintenance haemodialysis. J Viral Hepat 1994; 1:65-71.
5. Sampietro M, Badalamenti S, Salvadori S, et al. High prevalence of a rare hepatitis C virus in patients treated in the same hemodialysis unit: evidence for nosocomial transmission of HCV. Kidney Int 1995; 47:911-7.
6. Lamballerie X, Olmer M, Bouchouareb D, Zandotti C, De Micco P. Nosocomial transmission of hepatitis C virus in haemodialysis patients. J Med Virol 1996; 49:296-302.
7. Sandhu J, Preiksaitis JK, Campbell PM, Carriere KC, Hessel PA. Hepatitis C prevalence and risk factors in the northern Alberta dialysis population. Am J Epidemiol 1999; 150:58-66.
8. Scotto G, Avcella F, Panunzio M, et al. Hepatitis C virus infection in four haemodialysis units of southern Italy: epidemiological report. Eur J Epidemiol 1999; 15:217-23.
9. Grethe S, Gemsa F, Monazahian M, et al. Molecular epidemiology of an outbreak of HCV in a hemodialysis unit: direct sequencing of HCV-HVR1 as an appropriate tool for phylogenetic analysis. Med Virol 2000; 60:152-8.
10. Rigopoulou E I, Stefanidis I, Liaskos C, et al. HCV-RNA qualitative assay based on transcription mediated amplification improves the detection of hepatitis C virus infection in patients on hemodialysis: Results from five hemodialysis units in central Greece. J Clin Virol 2005; 34:81-5.
11. Yasuda K, Okuda K, Endo N, et al. Hypoaminotransferasemia in patients undergoing long-term hemodialysis: clinical and biochemical appraisal. J Gastroenterol 1995; 109:1295-300.
12. Saab S, Martin P, Brezina M, Gitnick G, Yee Jr HF. Serum alanine aminotransferase in hepatitis c screening of patients on hemodialysis. Am J Kidney Dis 2001; 37:308-15.
13. Silini E, Bono F, Cerino A, et al. Virological features of hepatitis C virus infection in hemodialysis patients. J Clin Microbiol 1993; 31:2913-7.
14. Bukh J, Wantzin P, Krogsgaard K, et al. High prevalence of hepatitis C virus (HCV) RNA in dialysis patients: failure of commercially available antibody tests to identify a significant number of patients with HCV infection. Copenhagen Dialysis HCV Study Group. J Infect Dis 1993; 168:1343-8.
15. Sakamoto N, Enomoto N, Marumo F, Sato C. Prevalence of hepatitis C virus infection among long-term hemodialysis patients: detection of hepatitis C virus RNA in plasma. J Med Virol 1993; 39:11-5.
16. Schneeberger PM, Keur I, van der Vliet W, et al. Hepatitis C virus infections in dialysis centers in The Netherlands: a national survey by serological and molecular methods. J Clin Microbiol 1998; 36:1711-5.
17. Dalekos GN, Boumba DS, Katopodis K, et al. Absence of HCV viraemia in anti-HCV-negative haemodialysis patients. Nephrol Dial Transplant 1998a; 13:1804-6.
18. Pereira BJ, Natov SN, Bouthot BA, et al. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int 1998; 53:1374-81.
19. Hanafusa T, Ichikawa Y, Kishikawa H, et al. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Am J Transplant 1998; 66:471-6.
20. Batty Jr DS, Swanson SJ, Kirk AD, et al. Hepatitis C virus seropositivity at the time of renal transplantation in the United States: associated factors and patient survival. Am J Transplant 2001; 1:179-84.
21. Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. J Hepatol 1999; 29:257-63.
22. Gursoy M, Gur G, Arslan H, Ozdemir N, Boyacioglu S. Interferon therapy in haemodialysis patients with acute hepatitis C virus infection and factors that predict response to treatment. J Viral Hepat 2001; 8:70-7.
23. Degos F, Pol S, Chaix ML, et al. The tolerance and efficacy of interferon-alpha in haemodialysis patients with HCV infection: a multicentre, prospective study. Nephrol Dial Transplant 2001; 16:1017-23.
24. Schroter M, Feucht HH, Schafer P, Zollner B, Laufs R. High percentage of seronegative HCV infections in hemodialysis patients: the need for PCR. Intervirology 1997; 40:277-8.
25. Carneiro MA, Martins RM, Teles SA, et al. Hepatitis C prevalence and risk factors in hemodialysis patients in Central Brazil: a survey by polymerase chain reaction and serological methods. Mem Inst Oswaldo Cruz 2001; 96:765-9.